Neovasc’s Reducer Shows Promise For Refractory Angina
This article was originally published in The Gray Sheet
Executive Summary
In a small but sham-controlled trial Neovasc’s balloon-expandable implant significantly improved symptoms and quality of life in patients with refractory angina who are not candidates for other revascularization procedures. Reducer works by increasing pressure in the coronary sinus.
You may also be interested in...
Neovasc Sees Opportunities In Refractory Angina And Mitral Regurgitation Markets
Neovasc Inc. is targeting two highly underserved markets in cardiology – refractory angina and mitral valve disease – with unique transcatheter solutions. The angina device, called the Neovasc Reducer, is expected to enter the European market early next year.
US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month
Two gene therapies and two novel inhibitors of JAK kinases are among the upcoming goal dates from the Pink Sheet’s US FDA Performance Tracker.
Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings
More formal meetings are available for in-person sessions with the US FDA. Also, CBER Director Peter Marks offers advice for conducting meetings, from how to do hybrid right to how to include patient groups and foreign regulators.